Establishes prescription drug pricing disclosure requirements and measures to reduce prescription drug costs.
Impact
The implementation of A3245 is expected to impact state laws significantly by introducing explicit regulations around prescription drug pricing practices. This could lead to reduced costs for consumers and an increased accountability of PBMs and drug manufacturers. By allowing the newly established Prescription Drug and Biological Product Review Commission to assess pricing and potentially set maximum allowable prices, the bill aims to tackle instances of excessive pricing and promote fair competition amongst drug providers.
Summary
Assembly Bill 3245 introduces a framework for prescription drug pricing disclosure aimed at enhancing transparency and reducing costs for consumers in New Jersey. The bill mandates pharmacy benefit managers (PBMs) to disclose pricing details for prescription drugs, particularly generic options, ensuring that purchasers are informed about pricing methodologies. Additionally, it establishes a toll-free hotline for consumers and pharmacists to access information related to drug pricing and safety, thereby fostering better communication and transparency in the marketplace.
Contention
While proponents argue that the bill will provide much-needed relief to consumers facing high drug prices, detractors raise concerns about the regulatory burden it may impose on pharmaceutical companies and PBMs. Critics might argue that stringent pricing controls could deter drug manufacturers from entering the market, ultimately impacting the availability of essential medications. The balance between preventing price gouging and ensuring a competitive drug market is likely to be a focal point of ongoing discussions surrounding the bill.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
An act to amend Section 4073.5 of the Business and Professions Code, to amend Section 1367.22 of the Health and Safety Code, and to add Section 10123.190 to the Insurance Code, relating to prescription drugs.
A bill for an act relating to pharmacy benefits managers, pharmacies, prescription drugs, and pharmacy services administrative organizations, and including applicability provisions. (Formerly SSB 1074.) Effective date: 07/01/2025. Applicability date: 07/01/2025.